{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06003075",
            "orgStudyIdInfo": {
                "id": "85869"
            },
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "Induction Chemo-Nivo in Unresectable Stage III NSCLC",
            "officialTitle": "Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "induction-chemo-nivo-in-unresectable-stage-iii-nsclc"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-15",
            "studyFirstSubmitQcDate": "2023-08-15",
            "studyFirstPostDateStruct": {
                "date": "2023-08-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Ralph G Zinner",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Ralph G Zinner",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Bristol-Myers Squibb",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Lung Cancer, Nonsmall Cell",
                "Lung Cancer Stage III"
            ],
            "keywords": [
                "Nivolumab",
                "unresectable"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Chemo, biopsy, surgery with option for post op chemo or no surgery with concurrent chemo",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 37,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Combination Chemotherapy and Nivolumab and Surgery",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with lung cancer receiving combination therapy with surgery",
                    "interventionNames": [
                        "Combination Product: Nivolumab and Chemotherapy",
                        "Drug: Nivolumab",
                        "Procedure: Post Induction Surgery",
                        "Radiation: Post Induction XRT"
                    ]
                },
                {
                    "label": "Combination Chemotherapy and Nivolumab and Radiation",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with lung cancer receiving combination therapy with radiation",
                    "interventionNames": [
                        "Combination Product: Nivolumab and Chemotherapy",
                        "Drug: Nivolumab",
                        "Radiation: Post Induction XRT"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Nivolumab and Chemotherapy",
                    "description": "3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks",
                    "armGroupLabels": [
                        "Combination Chemotherapy and Nivolumab and Radiation",
                        "Combination Chemotherapy and Nivolumab and Surgery"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation",
                    "armGroupLabels": [
                        "Combination Chemotherapy and Nivolumab and Radiation",
                        "Combination Chemotherapy and Nivolumab and Surgery"
                    ],
                    "otherNames": [
                        "NIVO"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Post Induction Surgery",
                    "description": "Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles",
                    "armGroupLabels": [
                        "Combination Chemotherapy and Nivolumab and Surgery"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Post Induction XRT",
                    "description": "Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.",
                    "armGroupLabels": [
                        "Combination Chemotherapy and Nivolumab and Radiation",
                        "Combination Chemotherapy and Nivolumab and Surgery"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Response rate after induction",
                    "description": "post induction radiographic response by cat scan",
                    "timeFrame": "9 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Toxicity",
                    "description": "To assess safety, investigators will evaluate the rate of toxicity as defined by the Common Toxicity Criteria for Adverse Effects (CTCAE) scoring system.",
                    "timeFrame": "through study completion, up to 18 months"
                },
                {
                    "measure": "Percent of participants receiving surgery",
                    "description": "Rate of converting non-surgical stage III(A-C) to surgically resectable disease",
                    "timeFrame": "date of surgery, approximately 10 weeks"
                },
                {
                    "measure": "Pathologic complete response (pCR)",
                    "description": "Number of participants with Pathologic Complete Response. Pathologic complete response (pCR) is defined by a surgical pathology specimen",
                    "timeFrame": "post surgery, approximately 10 weeks"
                },
                {
                    "measure": "Major pathological response (MPR)",
                    "description": "MPR rate, defined as number of participants with \u2264 10% residual tumor in lung and lymph nodes",
                    "timeFrame": "post surgery, approximately 10 weeks"
                },
                {
                    "measure": "Progression free survival (PFS)",
                    "description": "PFS is defined as the duration of time from start of treatment to time of disease progression or death, whichever occurs first.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "overall survival (OS)",
                    "description": "defined as the duration of time from start of treatment to time of death",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Change in patient-reported Quality of Life as measured by FACT-TOI",
                    "description": "patient-reported Quality of Life as measured by FACT-TOI (Functional Assessment of Cancer Therapy - Trial Outcome Index); defined as the sum of the scores of the Physical Well-Being (PWB), Functional Well-Being (FWB), and LCS. PWB, FWB, and LCS (lung cancer scale) scores obtained from 7-item questionnaires from the FACT-L (Version 4.0). Questions are on a 5-point scale from 0-4, where 0 = \"not at all\" and 4 = \"very much.\" Scores range from 0 to 84; higher score indicates better physical aspects of quality of life (QoL).",
                    "timeFrame": "through study completion, up to 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Squamous and non-squamous non-small cell lung cancer that is at baseline, unresectable stage IIIA-IIIC (8th edition AJCC) and not previously treated\n* PD-L1 level needs to be measured with values 0-100% eligible\n* EGFR/ALK/ROS1 Wild Type or unknown genetic alterations in these genes\n* ECOG Performance Status \u2264 1\n* Adequate organ and marrow function\n* Adequate pulmonary reserve (e.g., FVC, FEV1, TLC, FRC, and DLCO) capable of tolerating the proposed lung resection\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Clinical risk assessment of cardiac function using the New York Heart Association Functional Classification class 2B or better\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment\n* Any prior radiotherapy to the lung\n* Any prior treatment for NSCLC\n* Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* Any history of a severe hypersensitivity reaction to any monoclonal antibody\n* Any history of allergy to the study drug components\n* primary tumors involving the esophagus\n* pancoast tumors\n* Patients cannot have primary tumors which would remain unresectable\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study\n* Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications\n* Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg\n* previous malignancies\n* history of interstitial lung disease\n* Patients requiring continuous supplemental oxygen\n* Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy\n* Active systemic infection requiring therapy\n* Patients with uncontrolled intercurrent illness\n* Patients with psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant or lactating women",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yvonne Taul, RN",
                    "role": "CONTACT",
                    "phone": "859-323-2354",
                    "email": "yvonne.taul@uky.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ralph Zinner, MD",
                    "affiliation": "University of Kentucky",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kentucky",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40506",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yvonne Taul, RN",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Lung Cancer, Nonsmall Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M1668",
                    "name": "Docetaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M264",
                    "name": "Pemetrexed",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}